Webdisclosure.com

Search

NEOVACS (EPA:ALNEV) Neovacs S.A. signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris

Directive transparence : information réglementée

12/10/2016 11:05
DGAP-News: Neovacs S.A. / Key word(s): Alliance Neovacs S.A. signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris 12.10.2016 / 11:05 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE ( PRESS RELEASE ( PRESS RELEASE NEOVACS SIGNS A COOPERATION AGREEMENT WITH THE DEPARTMENT IMMUNOLOGY OF DIABETES AT THE REPUTED HOSPITAL COCHIN IN PARIS To collaborate on development of new diabetes treatment using Neovacs' Kinoid Technology Paris, October 12, 2016 - NEOVACS (Alternext Paris: ALNEV PEA-PME eligible), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced a collaboration with Doctor Agnès Lehuen and Professor Christian Boitard, who are leading the laboratory for Research in Immunology of Diabetes at the reputated Cochin Hospital in Paris. The goal of this collaboration is to achieve proof of concept for the use of Neovacs' IFNa Kinoid in the treatment of Type 1 diabetes. As part of this collaboration, Doctor Lehuen and Professor Boitard's teams will jointly conduct research with scientists from Neovacs on INFa Kinoid in NOD models (Non-Obese Diabetic mice - the most relevant mouse model for this disorder). Existing scientific publications offer a significant body of evidence to support the involvement of IFNa in Type 1 diabetes . This preclinical study aims to determine whether the use of the IFNa Kinoid vaccine can control this disorder by producing polyclonal neutralizing antibodies to Interferon alpha. Neovacs has already demonstrated in a Phase I /II study in lupus that anti- interferon antibodies have a biological activity capable of neutralizing the IFN signature, with a long-term positive effect . The same principle could be applied in Type 1 diabetes, which is an autoimmune disease also having an IFNa signature as observed in Lupus, and characterized by an overexpression of this cytokine (IFN alpha). According to Miguel Sieler, CEO of Neovacs: "This collaboration confirms the interest in our technology and its potential. It also supports our confidence in the development of therapeutic vaccines, especially with our INFa kinoid. We are very pleased to work with the Cochin Hospital teams in the Department of Immunology of Diabetes. It is urgent to address the unmet medical needs associated with Type 1 diabetes, and we believe that our technology has the potential to meet the expectations of the scientific community in this field. We are confident that this collaboration will produce actionable results and will provide important answers about developing a targeted treatment for Type 1 diabetes, responding to the concerns of patients." Dr. Agnes Lehuen and Professor Christian Boitard also explained: "This collaboration with Neovacs fits perfectly into our research focus. Indeed, faced with the rapid increase in patients affected by Type 1 diabetes, we need to find innovative ways to treat this disease and Neovacs' approach is particularly interesting." About Diabetes Diabetes is a disease that affects, according to WHO**, 422 million people worldwide, including 4 million in France and a rapid progression that could include 622 million patients by 2040. Notably, 10% of these patients have the auto immune form of type 1 diabetes. ** Source: World Report on Diabetes, published by WHO, April 2016 About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN?-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, please visit www.neovacs.fr Contacts NEOVACS Charlène Masson +33 (0)1 53 10 93 00 cmasson@neovacs.com Investor Relations - Financial Communications Germany - MC Services Raimund Gabriel +49-89-210228-30 raimund.gabriel@mc-services.eu --------------------------------------------------------------------------- 12.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service --------------------------------------------------------------------------- 511027 12.10.2016